PCDH10 and plasma cell myeloma: In addition to the aforementioned CRC, GC, PC, cervical and endometrial cancers, Pcdh10 loss has been observed in non-small-cell lung cancer (NSCLC; (Tang et al. 2012), nasopharyngeal and esophageal cancer (Ying et al. 2006), bladder cancer (Lin et al. 2012, 2013), hepatocellular carcinoma (Fang et al. 2013; Bing et al. 2018), multiple myeloma (Li et al. 2012a), lymphoid malignancies (Narayan et al. 2013), medulloblastoma (Bertrand et al. 2011), breast cancer (Liu et al. 2018b), and prostate cancer (Li et al. 2011), implying that Pcdh10 plays an oncosuppressor role in tumors.